| Release Date: March 1, 2009 | Expiration Date: March 1, 2011 | |
Continuing Education for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 2 hours (0.20 CEUs) of continuing education credit (program number 204-000-09-401-H01P).
Methods and Format
This web-based continuing education activity was developed based upon a satellite symposium presented during the 2008 Annual Meeting of the American College of Clinical Pharmacy. It consists of two case studies. The case studies are designed to be interactive, with questions posed to the participant at several points. After responding to each question, you will see the correct response and an explanation. Please respond to each question, even if you are unsure of your answer. These questions are for educational purposes only; your answers will not impact your CE credit for the program.
Participants must complete the entire online case study and post-program survey to receive continuing education credit. Participants may print their official statements of continuing education credit immediately. The estimated time to complete this activity is 2 hours. This activity is provided free of charge.
Target Audience
This continuing education activity was planned to meet the needs of pharmacists who treat, instruct, or otherwise participate in the care of patients with acute coronary syndrome.
Activity Content
This web-based, case-based continuing education activity applies clinical practice guidelines and recent clinical research results to two acute coronary syndrome patient cases.
Learning Objectives
After completing this application-based activity, the participant should be able to:
- Incorporate into clinical practice the recommendations for antithrombotic drug therapy in current evidence-based guidelines for the management of patients with acute coronary syndrome (ACS) to improve clinical outcomes.
- Recommend appropriate antithrombotic drug therapy for a patient with non-ST-segment elevation myocardial infarction or unstable angina, and explain the scientific basis for the recommendation.
- Recommend appropriate antithrombotic drug therapy for a patient with ST-segment elevation myocardial infarction, and explain the scientific basis for the recommendation.
- Identify an indication for triple antithrombotic therapy and compare and contrast the potential benefits and risks of therapy in patients with ACS.
Faculty
Sarah A. Spinler, Pharm.D., FCCP, BCPS (AQ Cardiology)
Professor of Clinical Pharmacy
Philadelphia College of Pharmacy
University of the Sciences in Philadelphia
Philadelphia, Pennsylvania
Zachary A. Stacy, Pharm.D., BCPS
Associate Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri
Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology)
Associate Professor of Clinical Pharmacy
University of Colorado Denver - School of Pharmacy
Clinical Coordinator
University of Colorado Hospital
Denver, Colorado
Disclosure Statements
In accordance with the Accreditation Council for Continuing Medical Education's and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP Advantage requires that all individuals involved in the development of activity content disclose their relevant financial relationships and that conflicts of interest be identified and resolved prior to delivery of the activity.
The faculty and planners report the following relationships:
Faculty
Sarah A. Spinler, Pharm.D., FCCP, BCPS (AQ Cardiology), declares that she has served on the speakers bureau for Bristol-Myers Squibb, GlaxoSmithKline, and sanofi-aventis. She also reports that she has served as a consultant for sanofi-aventis and The Medicines Company.Planners
Zachary A. Stacy, Pharm.D., BCPS, declares that he has served on the speakers bureau for sanofi-aventis.
Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology), declares that he has served as a consultant for The Medicines Company and sanofi-aventis.
Susan R. Dombrowski, M.S., R.Ph., declares that she has no relationships pertinent to this activity.
Kristi N. Hofer, Pharm.D., declares that she has no relationships pertinent to this activity.
This activity is planned and coordinated by ASHP Advantage.
It is supported by an educational grant from sanofi-aventis U.S.